Abbonarsi

riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma - 18/06/25

Doi : 10.1016/j.jaad.2025.02.076 
Anokhi Jambusaria-Pahlajani, MD, MSCE a, Vincent Jeanselme, PhD b, David M. Wang, MD c, Nina A. Ran, MD, MS c, Emily E. Granger, MD d, Javier Cañueto, MD e, David G. Brodland, MD f, David R. Carr, MD, MPH g, Joi B. Carter, MD h, John A. Carucci, MD, PhD i, Kelsey E. Hirotsu, MD j, Emily E. Karn, MS c, Shlomo A. Koyfman, MD k, Aaron R. Mangold, MD l, Fabio Muradás Girardi, MD, MSc m, Kathryn T. Shahwan, MD g, Divya Srivastava, MD n, Allison T. Vidimos, RPh, MD o, Tyler J. Willenbrink, MD f, Ashley Wysong, MD, MS p, William Lotter, PhD q, Emily S. Ruiz, MD, MPH c,
a Division of Dermatology, University of Texas, Austin, Texas 
b MRC Biostatistics Unit, University of Cambridge, Cambridge, UK 
c Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts 
d Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland 
e Department of Dermatology, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain 
f Zitelli and Brodland P.C., Pittsburgh, Pennsylvania 
g Department of Dermatology, The Ohio State University Medical Center, Columbus, Ohio 
h Department of Dermatology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 
i Department of Dermatology, New York University School of Medicine, New York, New York 
j Department of Dermatology, Stanford School of Medicine, Palo Alto, California 
k Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 
l Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona 
m Department of Head and Neck Surgery, Ana Nery Hospital, Santa Cruz do Sul, RS, Brazil 
n Department of Dermatology, University of Texas Southwestern School of Medicine, Dallas, Texas 
o Department of Dermatology, Cleveland Clinic, Cleveland, Ohio 
p Department of Dermatology, University of Nebraska Medical Center, Omaha, Nebraska 
q Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts 

Correspondence to: Emily S. Ruiz, MD, MPH, Department of Dermatology, Brigham and Women's Hospital, 1153 Centre St, Suite 4J, Boston, MA 02130. Department of Dermatology Brigham and Women's Hospital 1153 Centre St, Suite 4J Boston MA 02130

Abstract

Background

Cutaneous squamous cell carcinoma (CSCC) is a prevalent disease for which improved risk stratification strategies are needed.

Objective

To develop a novel prognostic model (herein “riSCC”) for CSCC and compare riSCC performance to Brigham and Women's Hospital and American Joint Committee on Cancer Staging eighth edition T staging systems.

Methods

Retrospective 12-center, multinational cohort study of CSCCs from 1991 to 2023. Clinical and pathologic risk factors, treatments, and outcomes were collected. Fine-Gray model was employed for each outcome with inverse probability of treatment weighting. A final model was trained for prospective use and estimation of hazard ratios.

Results

Twenty-three thousand one hundred sixty-six localized CSCC tumors were included. riSCC prognostic model performed superiorly to American Joint Committee on Cancer eighth edition and Brigham and Women's Hospital T staging for all outcomes. At 5 years, the C-index for riSCC ranged from 0.74 for local recurrence to 0.87 for disease specific death.

Limitations

Retrospective study design.

Conclusion

riSCC prognostic model offers fine-grained risk estimates and improved stratification for important CSCC outcomes compared to T staging systems.

Il testo completo di questo articolo è disponibile in PDF.

Key words : American Joint Committee on Cancer eighth edition, Brigham and Women's Hospital T Staging, cutaneous oncology, cutaneous squamous cell carcinoma, metastasis, Mohs micrographic surgery, nonmelanoma skin cancer, oncology, outcomes, recurrence

Abbreviations used : AJCC8, BWH, CSCC, DSD, ITM, LR, LVI, MMS, NM, PNI, WLE


Mappa


 Drs Jambusaria-Pahlajani, Ruiz and Authors Jeanselme, Lotter are contributed equally.
  Funding sources: Supported in part by the American College of Mohs Surgery (ACMS) Foundation ; WL is supported by grant R21EB035247 .
 Patient consent: Not applicable.
 IRB approval status: Reviewed and approved by all 12 institutions.


© 2025  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 93 - N° 1

P. 73-81 - luglio 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Reported psychiatric adverse events among isotretinoin users: Monitoring priorities from a 20-year FDA Adverse Event Reporting System database study
  • Wenjia Nie, Xiaopeng Wu, Yuting Xia, Liyun Zheng, Hengcheng Lu
| Articolo seguente Articolo seguente
  • Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: Pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies
  • David Pariser, Dee Anna Glaser, James Del Rosso, Neal Bhatia, Deirdre Hooper, Mark S. Nestor, Stacy Smith, Joel Schlessinger, Adelaide Hebert, Patricia S. Walker

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.